64) was well tolerated in 34 immunosuppressed patients with cancer and may have favorabl |
65) d the prevalence of medical conditions in patients with cancer and their impact on o |
66) of strategically enhancing management of patients with cancer at risk for this toxi |
67) cribe the terminal hospitalization LoS of patients with cancer managed by a hospital |
68) s, in both experimental animal models and patients with cancer. |
69) likely to result in improved outcomes for patients with cancer. |
70) Patients with congenital heart disease and |
71) aphics, clinical spectrum, and outcome of patients with congenital factor VII (FVII) |
72) n, the complete understanding of grown-up patients with congenital hart disease is m |
73) arrest (SCA) is a major cause of death in patients with congenital heart disease (CH |
74) The patients with congenital heart disease per |
75) y to reason about mental states, in adult patients with congenital heart disease. |
76) xchange (WCX) from Cohort 1, including 65 patients with RA and 41 healthy controls ( |
77) Many HTLV-1-positive patients with RA are assumed to exist; how |
78) is necessary to identify ways of helping patients with RA transition to—and maint |
79) of anti-TNF biologics in HTLV-1-positive patients with RA. |
80) festyle, disease and therapy variables in patients with RA. |
81) syndrome was identified in 44 and 41% of patients with and without PsA, elevated bl |
82) ar comorbidities were common in psoriasis patients with and without PsA, suggesting |
83) nitor the stability of dental implants in patients with and without a history of rad |
84) paper reports on the study of Swedish MI patients with and without coeliac disease |
85) pressure (BP) control among hypertensive patients with and without diabetes. |
86) ADMA; a marker of ED), in newly diagnosed patients with hypertension (n = 101; 61 fe |
87) enomic DNA obtained from 224 persons (125 patients with hypertension and 99 healthy |
88) to these groups of patients when managing patients with hypertension. |
89) erial stiffness and ED in newly diagnosed patients with hypertension. |
90) pear to be the most efficacious agents in patients with hypertension. |
91) o transplanting an islet preparation into patients with type 1 diabetes. |
92) elease both in healthy individuals and in patients with type 2 diabetes (T2DM). |
93) ction and clinical efficacy and safety in patients with type 2 diabetes, hyperlipide |
94) investigate female sexual dysfunction in patients with type 2 diabetes. |
95) The patients with type I recessive congenital |
96) A total of 306 patients with STEMI pPCI were evaluated. |
add keyword